A 55-year-old female with HFrEF (EF 30%) and NYHA Class II symptoms despite optimal doses of sacubitril/valsartan and metoprolol succinate, presents for follow-up. Her creatinine is 0.9 mg/dL, potassium 4.2 mEq/L. Which medication should be considered next to further reduce morbidity and mortality?

Question

BrainForge Quiz · Accepted Answer

C) Spironolactone. Mineralocorticoid receptor antagonists (MRAs) such as spironolactone are recommended for patients with HFrEF (EF ≤ 35%) and NYHA Class II-IV symptoms, already on an ARNI and beta-blocker, to further reduce morbidity and mortality, provided kidney function and potassium levels are acceptable.

A 55-year-old female with HFrEF (EF 30%) and NYHA Class II symptoms despite optimal doses of sacubitril/valsartan and metoprolol succinate, presents for follow-up. Her creatinine is 0.9 mg/dL, potassium 4.2 mEq/L. Which medication should be considered next to further reduce morbidity and mortality?

✓ Correct Answer: Option C

Related USMLE Exam Prep Questions